Table 2 Outcomes of the study

Primary outcome

Grade 2 or higher peripheral neuropathy (proportion)

Secondary

All grades of peripheral neuropathy (proportion)

Change in ulnar/median/sural nerve conduction velocity (compared to baseline) and 3 months after therapy cessation (percentage change)

Time to develop peripheral neuropathy (days)

Patient-reported outcomes using the EORTC QLQ-CIPN20 questionnaire

Adherence with oral gabapentin

Peripheral neuropathy-related dose changes in paclitaxel

Adverse events (NCI CTCAE version 5.0)

Autonomic nervous system function (orthostatic fall in systolic blood pressure and heart rate variability with deep breathing)